Global HER2-Negative Breast Cancer Market 2015 – 2019.pdf

Text-only Preview

Global HER2-Negative Breast Cancer Market 2015-2019
Global HER2-Negative Breast Cancer Market 2015-2019 is the latest addition to
industry research reports collection. The analysts forecast global HER2-negative breast cancer market to
grow at a CAGR of 15.94% over the period 2014-2019.
Read this 50 Pages Report on Global HER2-Negative Breast Cancer Market 2015-2019. The report
provides 18 Exhibits.
HER2-negative breast cancer is a subtype of breast cancer and is the condition when the HER2 is
expressed less in the tumor. According to the American Society of Clinical Oncology, most of the
patients with breast cancer are known to have HER2-negative breast cancer. HER2-negative breast
cancer patients can also be hormone receptor positive (HR+). The HER2 protein is found on the outer
surface of the breast cells, and the hormone receptors are found inside breast cells. The cancers that
have detectable hormone receptors are known as HR+ breast cancer, and those with HER2-negative
have a low level of HER2 gene or the HER2 protein.
HER2-negative breast cancer can also be HR+ and then the most preferred therapy is hormone therapy.
These patients can be treated with chemotherapy or targeted therapy to improve their condition. It can
also be treated with platinum-based drugs, and drugs such as capecitabine, eribulin, gemcitabine,
ixabepilone, and vinorelbine. These drugs have several adverse effects on patients as some of them can
attack the healthy cells of the body while destroying the malignant cells.
Covered in this report
This report covers the present scenario and the growth prospects of the global HER2-negative breast
cancer market for the period 2015-2019. To calculate the market size, the report considers revenue
generated from the sales of various off-label and branded drugs and the expected launch of drug
candidates intended to be used in the treatment of HER2-negative breast cancer.
Single User License: US $2500;
Buy the Report @
Alternatively can get Discount on the Report @
Based on type of drug molecule, the market is segmented as follows:
Small molecules
Based on route of administration, the market is segmented as follows:
This report includes a discussion of the market in the following three regions:
Americas (the US, Canada, Mexico, and Brazil)
EMEA (the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as
Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE)
APAC (Japan, China, Australia, Singapore, South Korea, and India)
The report, Global HER2-Negative Breast Cancer Market 2015-2019, has been prepared based on an in-
depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA;
it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects
in the coming years. The report includes a discussion of the key vendors operating in this market.
The report recognizes the following companies as the key players : F. Hoffmann-La Roche, Novartis and
Other Prominent Vendors in the market are: AbbVie, AstraZeneca, BioMarin, Bristol-Myers Squibb, Eisai,
Eli Lilly, Galena Biopharma, Incyte, Merck, Merck Serono, Merrimack, Nektar, and Tesaro.
Key Market Driver - Significant unmet needs
Inquire Before buying the Report @
.Key Market Challenges -Premium-priced therapies
Key Market Trend - Emerging therapies
Key Questions Answered in this Report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Table of Contents for Report is Available @
Browse All Reports on Therapeutics Market.
Contact [email protected] / Call +1 888 391 5441 for further information on “Global HER2-
Negative Breast Cancer Market 2015-2019” report OR for any other market research and intelligence
needs you may have for your business.
NOTE: This Report Is NOT Free Of Charge.